Actelion Pharmaceuticals Ltd (ATLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Actelion Pharmaceuticals Ltd (Actelion) is a biopharmaceutical company, which strives to discover, develop and commercialize innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.
Actelion Pharmaceuticals Ltd (ATLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Actelion Pharmaceuticals Ltd (Actelion) is a biopharmaceutical company, which strives to discover, develop and commercialize innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.
Actelion Pharmaceuticals Ltd (ATLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
3
List of Tables 5
List of Figures 5
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Enamine Expands Agreement with Actelion 14
SynAging Extends Agreement with Actelion Pharma 15
Handok Enters into Agreement with Actelion Pharmaceuticals 16
Actelion Forms Joint Venture with Max Planck Society 17
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18
Licensing Agreements 19
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 20
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 21
Gour Medical Enters into Licensing Agreement with Actelion Pharma 22
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 23
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 25
Biotoscana Extends Licensing Agreement With Actelion Pharma For Tracleer 26
Equity Offering 27
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 27
Debt Offering 28
Actelion Pharma Completes Private Placement Of Convertible Bonds For US$254 Million 28
Acquisition 29
Johnson & Johnson Acquires Actelion for USD30 Billion 29
Actelion Plans to Acquire ZS Pharma 31
Actelion Rejects Acquisition Offer from Shire 32
Tetraphase Pharma May Sell Itself 33
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 34
Actelion Pharmaceuticals Ltd - Key Competitors 36
Actelion Pharmaceuticals Ltd - Key Employees 37
Actelion Pharmaceuticals Ltd - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 42
Financial Announcements 42
Feb 14, 2017: Actelion announces excellent financial results for 2016 42
Oct 20, 2016: Excellent Operational Results - Supported By Outstanding Uptravi Launch - Financial Guidance Upgraded 46
Jul 21, 2016: Very Strong Performance in the First Half Of 2016 - Enhanced by Successful Uptravi US Launch 49
Apr 21, 2016: Very Strong Performance Continues In The First Quarter Of 2016 - Driven By Outcome-Based Pah Portfolio 53
Corporate Communications 56
Jun 09, 2017: Publication of Idorsias prospectus relating to the listing of Idorsia on SIX Swiss Exchange 56
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 58
Other Significant Developments 59
May 22, 2017: Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia 59
Nov 07, 2016: Actelion To Provide An Update On Advancements In Its Cardiovascular Pipeline In PAH And Beyond 61
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
List Of Tables
List of TablesActelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Actelion Pharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Enamine Expands Agreement with Actelion 14
SynAging Extends Agreement with Actelion Pharma 15
Handok Enters into Agreement with Actelion Pharmaceuticals 16
Actelion Forms Joint Venture with Max Planck Society 17
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 20
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 21
Gour Medical Enters into Licensing Agreement with Actelion Pharma 22
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 23
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 25
Biotoscana Extends Licensing Agreement With Actelion Pharma For Tracleer 26
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 27
Actelion Pharma Completes Private Placement Of Convertible Bonds For US$254 Million 28
Johnson & Johnson Acquires Actelion for USD30 Billion 29
Actelion Plans to Acquire ZS Pharma 31
Actelion Rejects Acquisition Offer from Shire 32
Tetraphase Pharma May Sell Itself 33
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 34
Actelion Pharmaceuticals Ltd, Key Competitors 36
Actelion Pharmaceuticals Ltd, Key Employees 37
Actelion Pharmaceuticals Ltd, Subsidiaries 38
RELATED REPORTS
Actelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report
Actelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance ReportActelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report
View ReportAntidiarrhoeals Drugs Global Market Report 2020 Including: 1) By Drug Class: Mucosal Protectants, Motility Modifying Drugs 2) By Application: Adults, Childrens 3) By Type: OTC drugs, Prescription Drugs Covering: GlaxoSmithKline, Actelion, Perrigo, Lupin, Glenmark Pharmaceuticals
Antidiarrhoeals Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global antidiarrhoeals drugs market.Reasons
View ReportActelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report
Actelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance ReportActelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report
View ReportGlenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review
Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review market research report available in single user pdf license with Aarkstore Enterprise at USD 300
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
